Search Within

Weinberg Fellows

Formats
  1. Meeting Abstract (1256)
  2. Journal Article (1061)
  3. Review (108)
  4. Editorial (54)
  5. Research Letter (31)
  6. Book Section (22)
  7. Correspondence (20)
  8. Guidelines (12)
  9. Conference Paper (2)
  10. Miscellaneous (1)
Groups
  1. Department of Medicine (2470)
  2. Solid Tumor Oncology Division (1885)
  3. Hematologic Malignancies, Division of (1191)
  4. GSK Faculty (1125)
  5. Department of Pathology and Laboratory Medicine (917)
  6. Epidemiology and Biostatistics (863)

More Groups

People
  1. Michael Berger (215)
  2. Marc Ladanyi (191)
  3. Pedram Razavi (184)
  4. Michael Offin (173)
  5. David Solit (166)
  6. Maria Carlo (166)

More People

Years
  1. 2025 (152)
  2. 2024 (370)
  3. 2023 (292)
  4. 2022 (347)
  5. 2021 (307)
  6. 2020 (307)

More Years

Publications
  1. Journal of Clinical Oncology (547)
  2. Blood (248)
  3. Annals of Oncology (98)
  4. Clinical Cancer Research (95)
  5. Journal of Thoracic Oncology (82)
  6. Cancer Research (80)

More Publications

Publishers
  1. American Society of Clinical Oncology (618)
  2. Elsevier Inc. (355)
  3. American Society of Hematology (282)
  4. American Association for Cancer Research (217)
  5. Nature Publishing Group (177)
  6. Oxford University Press (147)

More Publishers

Results (2567)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Clinical outcomes in NF2-mutated RCC treated with contemporary immunotherapy regimens
    Meeting Abstract

    Fitzgerald, K. N.; Duzgol, C.; Knezevic, A.; Jacobi, R.; Kotecha, R. R.; Aggen, D. H.; Carlo, M. I.; Shah, N. J.; Voss, M. H.; Feldman, D. R.; more...
    Cancer Research (2023)

    Fulltext@MSK | Save
  • Tumor immune microenvironment determinants of response to lenvatinib and a PD-1 blockade in clear cell renal cell carcinoma
    Meeting Abstract

    Vuong, L.; Kuo, F.; Jiang, H.; Mascareno, E. A.; Rappold, P.; Sabio, E.; Weiss, K.; Cornish, A.; Reese, S.; Adlesic, M.; more...
    Cancer Research (2023)

    Fulltext@MSK | Save
  • Geriatric assessment and outcomes of allogeneic hematopoietic cell transplantation in older patients
    Meeting Abstract

    Dahi, P. B.; Shahrokni, A.; Flynn, J.; Devlin, S. M.; Chinapen, S. A.; Ayala, J.; Brown, S.; Bugen, S.; Cho, C.; Gyurkocza, B.; more...
    Bone Marrow Transplantation (2023)

    Fulltext@MSK | Save
  • Outcomes in patients with B-cell precursor acute lymphoblastic leukemia who received inotuzumab ozogamicin and proceeded to hematopoietic stem cell transplantation: A registry-based, observational study
    Meeting Abstract

    Marks, D.; de Lima, M.; Kebriaei, P.; Lanza, F.; Cho, C.; Popradi, G.; Zhang, M. J.; Zhang, F.; Welch, V.; Tikka, S.; more...
    Bone Marrow Transplantation (2023)

    Fulltext@MSK | Save
  • PD-1 blockade as curative intent therapy in mismatch repair deficient locally advanced rectal cancer
    Meeting Abstract

    Cercek, A.; Lumish, M.; Sinopoli, J.; Weiss, J.; Shia, J.; Stadler, Z.; Yaeger, R.; Smith, J. J.; Saltz, L.; Widmar, M.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Pan-cancer assessment of the impact of intronic variants on cancer development and progression
    Meeting Abstract

    Safonov, A.; Mehine, M.; Ceyhan-Birsoy, O.; Brown, D.; Bandlamudi, C.; Forbes, A.; Gazzo, A.; Selenica, P.; Shen, R.; Khurana, E.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Detection of alternative lengthening of telomeres (ALT) across cancer types based on tumor-normal multigene panel sequencing
    Meeting Abstract

    Heredia, J. B.; Diplas, B. H.; El Nahhas, O. S. M.; Selenica, P.; Pareja, F.; Mandelker, D.; Weigelt, B.; Riaz, N.; Rosen, E.; Sfeir, A.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Safety and efficacy of etigilimab (anti-TIGIT) with nivolumab (anti-PD1) in recurrent/advanced solid tumors
    Meeting Abstract

    McKean, M.; Dumbrava, E. E.; Hamid, O.; Merriam, P.; Call, J. A.; Feely, W.; Green, A.; Vaishampayan, U. N.; Moore, K. N.; Weroha, S.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Phase I study of ceralasertib (cerala) in combination with AZD5305 in patients (pts) with advanced/metastatic ovarian cancer (OC) previously treated with PARP inhibitors (PARPis)
    Meeting Abstract

    Shapiro, G. I.; Basu, B.; El-Khoueiry, A. B.; Postel-Vinay, S.; Im, S. A.; Rha, S. Y.; Friedman, C. F.; Italiano, A.; Kim, Y. M.; Lim, M. C.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Interim results from a phase I/II study of HPN328, a tri-specific, half-life (T1/2) extended DLL3-targeting T cell engager in patients (pts) with small cell lung cancer (SCLC) and other neuroendocrine neoplasms (NEN)
    Meeting Abstract

    Choudhury, N.; Jain, P.; Dowlati, A.; Thompson, J.; Johnson, M. L.; Mamdani, H.; Sanborn, R. E.; Schenk, E. L.; Aggarwal, R.; Sankar, K.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save